Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CLK2 | P49760 | 2/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | USP9X | Q93008 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | ROS1 | P08922 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18891533 | 0.84 | ALDH1A1 (0.44) | ALDH1A1HPGDKDM4ETDP1MEN1 | |
| SCHEMBL7984520 | 0.75 | FFAR2 (0.40) | GRM5ALDH1A1MEN1KMT2A | |
| SCHEMBL11712255 | 0.75 | RAB9A (0.55) | GRM5ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL1861757 | 0.75 | RAB9A (0.55) | GRM5ALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL13723366 | 0.75 | XIAP (0.50) | ALDH1A1KDM4ETDP1MEN1KMT2A | |
| SCHEMBL21159432 | 0.75 | ALDH1A1 (0.49) | GRM5ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL24426603 | 0.75 | KDR (0.43) | GRM5CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14127502 | 0.75 | KDR (0.51) | GRM5CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL31143287 | 0.75 | KDR (0.51) | GRM5CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19456740 | 0.75 | GRM5 (0.36) | GRM5CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981854-B | Synthesis method of 2-amino-6- (1-alkyl piperidine-4-carbonyl) pyridine compound | 南京三元阳普医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11001600-B2 | Disubstituted compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| CN-110981854-A | Synthesis method of 2-amino-6- (1-alkyl piperidine-4-carbonyl) pyridine compound | 南京三元阳普医药科技有限公司 | 2020-04-10 | — | — | CN | disclosed |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180179236-A1 | DISUBSTITUTED COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICAL, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| CN-105658639-A | Alkynyl alcohols and methods of use | 豪夫迈·罗氏有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-9085578-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-21 | — | — | US | disclosed |
| US-9085578-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-21 | — | — | US | disclosed |
| US-20150045349-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2015-02-12 | — | — | US | disclosed |
| US-20150045349-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2015-02-12 | — | — | US | disclosed |
| US-20150045349-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2015-02-12 | — | — | US | disclosed |
| EP-2818473-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822352-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | GRM5 4624/4885CHRNB2 4048/4885CHRNA4 4758/4885 |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | GRM5 4624/4885CHRNB2 4048/4885CHRNA4 4758/4885 |
| US-20150045349-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | GRM5 1924/4885CHRNB2 3277/4885CHRNA4 3894/4885 |
| US-20180179236-A1 | DISUBSTITUTED COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | GRM5 2809/4885CHRNB2 4633/4885CHRNA4 4832/4885 |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | GRM5 4624/4885CHRNB2 4048/4885CHRNA4 4758/4885 |
| US-11001600-B2 | Disubstituted compounds for treatment of medical disorders | CFD, TFPI, CFH | GRM5 2809/4885CHRNB2 4633/4885CHRNA4 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.